Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-27 | Dr. Gary J. Nabel M.D., Ph.D. recently retired as Chief Scientific Officer, Global Research and Development, and Head of the North American R&D Hub at Sanofi. ... Dr. Nabel's broad experience and expertise within the pharmaceutical and biotech industries, as well as Dr. Nabel's history of leadership within the National Institutes of Health, provide the Board with valuable insights into many aspects of our business. |
| 2022-04-27 | Dr. Gary J. Nabel M.D., Ph.D. is currently President and CEO of ModeX Therapeutics Inc. ... The Audit Committee, which consists of directors Michael C. Planksy, James J. Antal, and Joseph W. Marshall, held four meetings during 2021. ... During the fiscal year ending December 31, 2021, the directors of SIGA received total compensation as shown in the following table: Gary J. Nabel: Fees Earned $24,478, Stock Awards $150,000, Option Awards $128,750, Total $303,228. |
| 2023-04-26 | Dr. Gary J. Nabel M.D., Ph.D. is currently President and CEO of ModeX Therapeutics Inc. ... Member of the Compensation Committee since November 2022. ... Director Compensation table shows total compensation of $205,763. |
| 2024-04-26 | Gary J. Nabel M.D., Ph.D. has served as a director of SIGA since June 2021. ... Dr. Nabel is currently President and CEO of ModeX Therapeutics Inc. ... The Board of Directors has determined that each of the members of the Compensation Committee is "independent" ... Member of the Compensation Committee. ... During the fiscal year ending December 31, 2023, the directors of SIGA received total compensation as shown in the following table: Gary J. Nabel: Fees Earned $52,500, Stock Awards $150,000, All Other Compensation $6,579, Total $209,079. |
Data sourced from SEC filings. Last updated: 2026-02-08